Algert Global’s Unity Biotechnology UBX Stock Holding History

Algert Global’s Portfolio UBX Stock Details UBX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-4,032	Closed	-$59K	–	1312
2021 Q4	$59K	Buy	4,032 +791	+24%	+$17.3K	0.01%	933
2021 Q3	$97K	Buy	+3,241	New	+$114K	0.01%	970
2021 Q1	–	Sell	-5,189	Closed	-$272K	–	535
2020 Q4	$272K	Hold	5,189	–	–	0.08%	313
2020 Q3	$180K	Buy	+5,189	New	+$329K	0.06%	324

Other funds holding UBX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

PVI

Pura Vida Investments New York $14.9M AUM 38.76% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

GCP

GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

FFVM

Founders Fund V Management San Francisco, California $2.16M AUM 77.37% 1-Year Est. Return

Algert Global's UBX Position: Q1 2022 in Review

Algert Global sold out of Unity Biotechnology (UBX) in Q1 2022, closing a stake of 4,032 shares — an estimated $59K sold.

Algert Global first reported a position in UBX in Q3 2020 and held it in 4 quarters. The position peaked at $272K in Q4 2020. 70 funds tracked by Wall St. Rank hold UBX as of Q1 2022.

Algert Global reported no remaining Unity Biotechnology position as of Q1 2022 after selling out during the quarter.
Algert Global sold 4,032 Unity Biotechnology shares in Q1 2022, an estimated $59K.
Algert Global first reported a position in Unity Biotechnology in Q3 2020 and held it in 4 quarters.
Algert Global's Unity Biotechnology position peaked at $272K in Q4 2020.
70 funds tracked by Wall St. Rank held Unity Biotechnology as of Q1 2022.

Based on Algert Global's 13F filing for Q1 2022, filed 16 May 2022.